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There have not been yet enough studies about eﬀects of beta glucan and gliclazide on oxidative stress created by streptozotocin in
the brain and sciatic nerve of diabetic rats. The aim of this paper was to investigate the antioxidant eﬀects of gliclazide and beta
glucan on oxidative stress and lipid peroxidation created by streptozotosin in brain and sciatic nerve. Total of 42 rats were divided
into 6 groups including control, diabetic untreated (DM) (only STZ, diabetic), STZ (DM)+beta glucan, STZ (DM)+gliclazide,
only beta glucan treated (no diabetic), and only gliclazide treated (no diabetic). The brain and sciatic nerve tissue samples were
analyzed for malondialdehyde (MDA), total oxidant status (TOS), total antioxidant status (TAS), oxidative stress index (OSI), and
paraoxonase (PON-1) levels. We found a signiﬁcant increase in MDA, TOS, and OSI along with a reduction in TAS level, catalase,
and PON-1 activities in brain and sciatic nerve of streptozotocin-induced diabetic rats. Also, this study shows that in terms of
these parameters both gliclazide and beta glucan have a neuroprotective eﬀect on the brain and sciatic nerve of the streptozotocin-
induced diabetic rat. Our conclusion was that gliclazide and beta glucan have antioxidant eﬀects on the brain and sciatic nerve of
the streptozotocin-induced diabetic rat.
1.Introduction
Diabetes mellitus (DM) is one of the most common chronic
metabolic disorders leading to complications in a number of
organ and systems. DM characterised by disturbed glucose
metabolism due to an absolute or relative insulin deﬁciency
aﬀects the central and peripheral nervous systems [1]. It is
reported that encephalopathy is the long-term neurological
complication of diabetes and is associated with cognitive
decline and increased risk of dementia [2]. Brain and nerve
tissues are two sites of diabetic organ damage [3]. Also,
it is reported that oxidative stress and apoptosis play an
important role in diabetes-induced tissue damage [4, 5].
DM, in hyperglicemia uncontrolled, initiates degenerative
processes that causes damage of brain and nerve tissues
because of excess oxidative stress. In diabetic complications,
oxidative stress results from an overproduction of reactive
oxygen/nitrogen species generated by glucose autoxida-
tion, mitochondria dysfunction, protein glycation and from
decreased antioxidant defenses [6].
One of the important goals of DM treatment is to
prevent its complications. To this end, there is accumulat-
ing evidence that supplementation antioxidant compounds
may oﬀer some protection against diabetic complications
[7]. Therefore, beta-glucan and gliclazide were selected as
possible protective materials of this study. Beta-glucans are
glucose polymers that are found in the cell walls of yeast,
fungi, and cereal plants. They are known to have beneﬁcial2 Experimental Diabetes Research
eﬀects on the immune system and are claimed to have no
toxic or adverse eﬀects. Natural products containing beta-
glucanshavebeenusedforthousandsofyearsforthebeneﬁts
of human health, but beta-glucans were only identiﬁed
as active components recently [8]. Beta-glucans have been
investigated extensively for immune stimulation eﬀects and
developedforthetreatmentofseveraldiseasesincludingcan-
cer, decubitus ulcer, and infectious diseases. Recent studies
have reported that beta-glucans could reduce hyperglicemia,
hyperlipidemia, and hypertension [9]. Several mechanisms
were suggested for the protective eﬀect of beta-glucan; one
of these mechanisms is related to antioxidant capacity of this
molecule. It was found that β-glucan is an antioxidant with
the scavenging ability lying between that of α-tocopherol,
which is known to be incorporated in the lipid bilayer,
and the water-soluble antioxidant, mannitol [10]. Therefore,
beta-glucans have great potential for the treatment of dia-
betes and associated neurological diseases including diabetic
neuropathy and encephalopathy. Thus, beta glucan can lead
new approaches for the prevention of diabetic neurologic
complications and vascular risk factors by reducing oxidative
damage of this molecule. However, there have not been
yet enough studies for its antioxidant actions on diabetic
brain and sciatic norve tissues. The aim of this study was to
investigate the antioxidant protective eﬀects of beta glucan
on brain and sciatic nerve tissues of streptozotocin-induced
diabetic rats.
Gliclazide which is another possible protective material
of this study, is a second-generation sulfonylurea hypo-
glycemic agent. It may show eﬀect as reduction in free
radical generation or an increase in free radical scavenging.
Also, gliclazide may contribute to the control of the phys-
iopathological mechanisms underlying both the process of
aging and type 2 diabetes by reducing oxidant stress and
DNA damage, improving antioxidant status [11]. In diabetic
experimental models, it has been reported that gliclazide
potentially protects the vasculature through improvements
in plasma lipids and platelet function [12]. However, there
have not been yet enough studies about its antioxidant
actions on diabetic brain and sciatic nerve tissues. Therefore,
in the present study, the protective eﬀects of gliclazide
against oxidative stress and lipid peroxidation created by
streptozotocinonbrainandsciaticnerveindiabeticratswere
investtigated.
2.MaterialsandMethods
2.1. Animals, Care, and Nutrition. This study was approved
by Dicle University Animal Ethical Committee and was car-
ried out in accordance with the “Animal Welfare Act and the
Guide for the Care and Use of Laboratory animals prepared
by the Dicle University, Animal Ethical Committee.” Female
Wistar Albino rats (250 ± 50g) were obtained from the
Animal labaratuaryof Dicle University. The rats were housed
in clean polypropylene cages having six rats per cage and
maintained under temperature controlled room (23 ± 2◦C)
with a photoperiod of 12h light and 12h dark cycle. The
rats were given standard pellets diet and water ad libitum
throughout the experimental period. All eﬀorts were made
to minimize animal suﬀering and to use only the number of
animals necessary to produce reliable scientiﬁc data.
2.2. Animals and Treatment. The rats were fasted overnight,
and diabetes was induced by a single dose via intraperitoneal
injection of streptozotocin solution (STZ). The experiment
was designed as a total of 28 days. A week after STZ
administration, their blood glucose values were measured
and were deﬁned as diabetic rats, that is, their blood glucose
values were above 250mg/dL. STZ caused the death of some
rats. At the end, 42 rats were divided into 6 groups including
control, diabetic untreated (only STZ, diabetic), diabetics
treated with beta glucan (STZ + beta glucan), diabetics
treated with gliclazide (STZ + gliclazide), only beta glucan
treated (beta glucan control, no diabetic), and only gliclazide
treated (gliclazide control, no diabetic). The beta-glucan
(Mustafa Nevzat Company, Turkey) used in this study is
1,3-1,6 beta-D-glucan in the microparticulate form, which
was prepared from the S. cerevisiae yeast. Beta glucan was
administeredorally(50mg/kgbodyweight)withagavagefor
21daysintheSTZ+betaglucanandbetaglucangroups.The
gliclazide(DIAMICRON,MustafaNevzatCompany,Turkey)
used in the tablet form was administered orally (10mg/kg
bodyweight)withagavagefor21daysintheSTZ+gliclazide
and only gliclazide groups. STZ solution was prepared as
follows: 24mg of STZ was dissolved in 1mL of 5mM
citrate buﬀer (pH 4.5) before the injection, and a volume
of 2.5mL/kg was administrated into each rat. The animals
were fasted overnight and diabetes was induced by a single
i.p. injection of a freshly prepared solution of STZ (CAS
number: 133 18883-66-4, 85882, Sigma-Aldrich) (50mg/kg
body weight) in 0.1M cold citrate buﬀer (pH 4.5). One week
after STZ administration, blood was taken from the lateral
veins of the tail, their blood glucose levels were measured
by a glucometer (ACCU-CHEK, Roche Diagnostics) using
a glucose oxidase method and the rats whose blood glucose
values were above 250mg/dL were accepted as diabetic [13].
After completion of 21 days for drug treatments, the animals
were sacriﬁced by cervical dislocation, and the brain and
sciatic nerve tissues were excised at 4◦C. The tissues were
washedwithice-coldsalineandimmediatelystoredat −50◦C
for biochemical analyses.
2.3. Biochemical Analyses. The excised cerebrum and sciatic
nerve tissue samples for biochemical analyses were weighed,
immediately stored at −50◦C. The cerebrum tissues cleaned
with 1.15% ice-cold KCl, minced, then homogenized in ﬁve
volumes (w/v) of the same solution. Assays were performed
on the supernatant of the homogenate that is prepared at
14.000rpm for 30min at +4◦C. The protein concentrationof
the tissue was measured by the method of Lowry [14]. Lipid
peroxidationlevelinthecerebrumwasexpressedasmalondi-
aldehyde (MDA). It was measured according to procedure of
Ohkawa et al. [15]. Catalase activity was measured according
to the method of Aebi [16]. Serum paraoxonase (PON-1)
activity was measured spectrophotometrically by modiﬁed
Eckerson method [17]. The TAS of supernatant fractions
was evaluated by using a novel automated and colorimetric
measurement method developed by Erel [18]. HydroxylExperimental Diabetes Research 3
radicals, the most potent biological radicals, are produced in
this method. In the assay, the ferrous ion solution present in
reagent 1 is mixed with hydrogen peroxide, which is present
in reagent 2. The subsequently produced radicals, such as
brown-colored dianisidine radical cations produced by the
hydroxylradicals,arealsopotentradicals.Usingthismethod,
the antioxidative eﬀect of the sample is measured against
the potent-free radical reactions initiated by the produced
hydroxyl radicals. The assay has excellent precision values
lower than 3%. The total antioxidant status (TAS) results are
expressed as nmol Trolox equivalent/mg protein. The total
oxidant status (TOS) of supernatant fractions was evaluated
by using a novel automated and colorimetric measurement
method developed by Erel [19]. Oxidants present in the
sample oxidize the ferrous ion-o-dianisidine complex to
ferric ion. The oxidation reaction is increased by glycerol
molecules, which are abundantly present in the reaction
medium. The ferric ion makes a colored complex with
xylenol orange in an acidic medium. The color intensity,
which can be measured spectrophotometrically, is related to
the total amount of oxidant molecules present in the sample.
The assay is calibrated with hydrogen peroxide, and the
results are expressed in terms of nmol H2O2 equivalent/mg
protein [20]. The TOS level to TAS level ratio was regarded
as the oxidative stress index (OSI). The unit of cerebrum
tissue TOS and TAS was μmole H2O2 Equiv./gram protein
and mmole H2O2 Equiv./gram protein, respectively. The
cerebrum tissue OSI value was calculated as follows: OSI
= ((TOS, μmole H2O2 Equiv./gram protein)/(TAS, μmole
H2O2 Equiv./gram protein) × 100) [21].
2.4. Statistical Analyses. The data was analyzed by using
Statistical Package for the Social Sciences version 11.5 (SPSS
11.5 for Windows, Chicago, IL, USA). The variables between
the groups were tested by Mann Whitney U test. A value of
P<0.05 indicates a signiﬁcant diﬀerence. Data are expressed
as mean ± S.D.
3. Results
In the rat brain, the MDA, TOS, TAS, and OSI level, catalase
and PON-1 enzyme activities are presented in Table 1.T h e r e
was a signiﬁcant depletion in the PON-1, catalase, and TAS
levels in the brain of the diabetic rat compared to the
control groups (for both parameters P<0.05). However,
beta glucan-treated diabetic rats signiﬁcantly reversed the
catalase, PON-1 and TAS back to normal levels compared
to untreated diabetic rats (for both parameters P<0.05).
PON-1 activity was signiﬁcantly higher in gliclazide-treated
diabetic group than untreated diabetic group in the brain
(P<0.05), but catalase activity and TAS level were not
signiﬁcant (for both parameters P>0.05). As can be seen
from Table 1, the level of MDA, TOS, and OSI in the brain
tissue was increased in untreated diabetic rats compared
with the rats of control group (for both parameters P<
0.05). However, MDA, TOS, and OSI levels were signiﬁcantly
reduced to gliclazide-treated diabetic group compared with
the untreated-diabetic group in brain tissue (for both
parameters P<0.05). Likewise, MDA, TOS, and OSI levels
were signiﬁcantly reduced to beta-glucan-treated diabetic
group compared with the untreated-diabetic group in brain
tissue (for both parameters P<0.05).
It was observed that medication similarly aﬀected both
tissue in the rat sciatic nerve compared with brain tissue. In
the rat sciatic nerve, the MDA, TOS, TAS, and OSI levels as
wellascatalaseandPON-1enzymeactivitiesarepresentedin
Table 2. There were no signiﬁcant diﬀerences in brain tissue
MDA, TOS, TAS, OSI, catalase, and PON-1 in both beta
glucan-treated group and gliclazide-treated group compared
to control group rats (P>0.05). There was a signiﬁcant
depletioninthePON-1,catalase,andTASlevelsinthesciatic
nerve of the diabetic rat compared to the control groups (for
both parameters P<0.05). However, beta-glucan-treated
diabetic rats signiﬁcantly reversed catalase, PON-1, and
TAS back to normal levels compared to untreated diabetic
rats (for both parameters P<0.05). PON-1 activity was
signiﬁcantly higher in gliclazide-treated diabetic group than
untreated diabetic group in the brain (P<0.05), but
catalase activity and TAS level were not signiﬁcant (for both
parameters P>0.05). As can be seen from Table 2, the
levels of MDA, TOS, and OSI in the sciatic nerve tissue
were increased in untreated diabetic rats compared with
the rats of control group (for both parameters P<0.05).
However, MDA, TOS, and OSI levels were signiﬁcantly
reduced to gliclazide-treated diabetic group compared with
the untreated-diabetic group in sciatic nerve tissue (for both
parameters P<0.05). Likewise, MDA, TOS, and OSI levels
were signiﬁcantly reduced to beta-glucan-treated diabetic
group compared with the untreated-diabetic group in sciatic
nerve tissue (for both parameters P<0.05).
4. Discussion
DM is a metabolic disorder with a globally rising prevalence
which can aﬀect the peripheral and central nervous system
[2, 22]. It is well known that oxidative stress is a contributor
to the development of complications in DM. There are
several lines of evidence indicating that oxidative stress
is increased in diabetic neuropathy and encephalopathy
[23, 24]. Streptozotocin-induced diabetes is a well-described
model of experimental diabetes that provides a relevant
example of endogenous chronic oxidative stress as a result
of hyperglycemia in diabetic brain [4].
Previous experimental studies in STZ-induced diabetic
rats have been suggested that the increased oxidative stress is
an important factor in the pathogenesis of the complications
[4]. For example, increased lipid peroxidation impairs
membrane function by decreasing membrane ﬂuidity and
causes free-radical-induced membrane lipid peroxidation
including increased membrane rigidity, decreased cellular
deformability, leading to various diseases [25]. Lipid peroxi-
dation is initiated by free radicals attack to membrane lipids,
generating large amounts of reactive products, which have
been implicated in diabetes and its complications. MDA is a
decomposition product of peroxidized polyunsaturated fatty
acids, end product of lipid peroxidation. Thus, MDA is a
marker of lipid peroxidation. In this study, the level of MDA
signiﬁcantly increased in the untreated diabetic rat sciatic4 Experimental Diabetes Research
Table 1: Biochemical parameters in all groups in the brain of rats.
Groups MDA
(nmol/gr protein)
TOS
(mmol H2O2 Eq./g protein)
TAS
(mmol Trolox Eq./g protein) OSI Catalase
(U/g protein)
PON-1 activity
(U/mg protein)
Control (I) 259.9 ±60.52 2 .0 ±8.20 .44 ±0.15 3 .6 ± 25.51 .19 ±0.14 0.72 ±0.29
Diabetic (II) 454.7 ±62.83 9 .7 ±3.50 .22 ±0.08 204.9±96.30 .65 ±0.15 0.30 ±0.05
Diabetic +
gliclazide (III) 367.4 ±47.63 2 .2 ±2.80 .29 ±0.04 113.7±17.10 .73 ±0.12 0.40 ±0.10
Diabetic + Beta
glucan (IV) 329.2 ±45.32 7 .0 ±5.90 .38 ±0.08 75.0 ± 26.91 .02 ±0.09 0.59 ±0.26
Gliclazide (V) 242.0 ±36.72 0 .5 ±6.30 .44 ±0.15 1 .01±28.71 .34 ±0.23 0.80 ±0.18
Beta glucan (VI) 257.0 ±55.02 1 .8 ±6.80 .46 ±0.11 52.7 ± 33.41 .30 ±0.26 0.71 ±0.20
P values
I-II 0.002 0.004 0.003 0.002 0.002 0.004
II-III 0.009 0.009 N.S. 0.009 N.S. 0.046
II–IV 0.002 0.004 0.012 0.002 0.002 0.016
I–VI N.S. N.S. N.S. N.S. N.S. N.S.
I–V N.S. N.S. N.S. N.S. N.S. N.S.
N.S: not signiﬁcant, MDA: malondialdehyde, TOS: total oxidant status, TAS: total antioxidant status, OSI: oxidative stress index, PON-1: paraoxonase.
Table 2: Biochemical parameters in all groups in the sciatic nerve of rats.
Groups MDA
(nmol/gr protein)
TOS
(mmol H2O2 Eq./g protein)
TAS
(mmol Trolox Eq./g protein) OSI Catalase
(U/g protein)
PON-1 activity
(U/mg protein)
Control (I) 17.6 ±3.11 1 .4 ±3.50 .16 ±0.01 70.7 ±23.00 .36 ±0.07 0.11 ±0.02
Diabetic (II) 30.2 ±4.22 0 .6 ±1.90 .08 ±0.03 299.4±161.90 .19 ±0.05 0.04 ±0.01
Diabetic +
gliclazide (III) 25.0 ±2.91 7 .7 ±2.50 .11 ±0.02 162.3 ±37.20 .21 ±0.03 0.06 ±0.01
Diabetic + Beta
glucan (IV) 23.0 ±1.31 4 .1 ±2.70 .14 ±0.03 108.4 ±41.50 .29 ±0.03 0.09 ±0.03
Gliclazide (V) 16.1 ±2.41 0 .7 ±3.20 .16 ±0.04 71.5 ±40.80 .39 ±0.07 0.12 ±0.03
Beta glucan
(VI) 17.1 ±3.61 1 .3 ±3.50 .17 ±0.04 73.6 ±45.20 .38 ±0.08 0.10 ±0.03
P values
I-II 0.002 0.004 0.002 0.002 0.002 0.002
II-III 0.017 0.025 N.S. 0.018 N.S. 0.021
II–IV 0.002 0.004 0.012 0.002 0.002 0.006
I–V N.S. N.S. N.S. N.S. N.S. N.S.
I–VI N.S. N.S. N.S. N.S. N.S. N.S.
N.S: not signiﬁcant, MDA: malondialdehyde, TOS: total oxidant status, TAS: total antioxidant status, OSI: oxidative stress index, PON-1: paraoxonase.
and brain tissues. And it was concluded that the increase
in lipid peroxidation might be a reﬂection of the decrease
in enzymatic and nonenzymatic antioxidants of defense sys-
tems in diabetic rats. Similarly, in previous studies, increased
MDA levels have been found in brain and sciatic nerve of
diabetic rats [4, 26]. Also, in our study, the reduced MDA
levels by both gliclazide and beta glucan likely demonstrate
that beta glucan and gliclazide might be agents to protect the
brain and nerve tissues against diabetic oxidative stress. In
one study, it has been reported that treatment with gliclazide
prevented the increase level of lipid peroxidation marker in
plasma and pancreas of diabetic rats. In another a study, it
hasbeenfoundthatMDAleveldecreasedfollowinggliclazide
treatment in patients with diabetes [25, 27]. Also, it has been
reported that gliclazide may be beneﬁcial by inhibition of
lipid and protein denaturation [28]. Similar to our study,
Delibas et al. reported that gliclazide treatment prevented
the elevation of MDA levels in hippocampus of diabetic
rats [29]. In addition to MDA level, measurement of TOS,
TAS, and OSI provides novel and reliable index of oxidative
s t r e s s .T h el e v e l so fo x i d a n t sc a na l r e a d yb em e a s u r e ds e p -
arately in the laboratory, but these measurements are time-
consuming and costly. The number of diﬀerent oxidants
in all biological samples makes it diﬃcult to measure each
oxidant separately. Assessment of TOS may be indicating the
level of all free oxidant radicals caused by diabetes-related
oxidative stress [30]. Likewise, the number of diﬀerent
antioxidants in all biological samples makes it diﬃcult to
measure each antioxidant separately. Thereby, TAS may be
an important factor providing protection from neurologicalExperimental Diabetes Research 5
damage caused by diabetes-related oxidative stress [31].
Therefore, we investigated both TAS and TOS by using new
measurement methods developed by Erel (2004, 2005) to
more accurately assess oxidative stress in this study [18, 19].
AlsoweevaluatedoxidativestresswithOSI,detectedbyusing
both TOS and TAS parameters. We found increased TOS and
OSIlevelsanddecreasedTASlevelandcatalaseactivityinthe
diabetic rats compared to control rats in the brain and sciatic
nerve tissues. At the same time, this study conﬁrms that
brain and sciatic nerve of diabetic rats show increased MDA,
TOS, and OSI levels along with reduced TAS and catalase.
These increases may be due to overproduction or decreased
excretion of oxidant substances. Because of the increase
in these oxidants and the decrease in total antioxidants,
the oxidative/antioxidative balance demonstrated to shift
towards the oxidative status in brain and sciatic nerve
tissues of diabetic rats in this study. Treatment with beta
glucan of diabetic rats was signiﬁcantly reduced to TOS and
OSI along with increased TAS level and catalase activity
compared to untreated diabetic rats in brain and sciatic
tissues. Because of the decrease in these oxidants and the
increase in these antioxidants, the oxidative/antioxidative
balance demonstrated to shift towards the antioxidative
status with beta glucan treatment in brain and sciatic nerve
tissues of diabetic rats. Additionally, there was no diﬀerence
in beta glucan group between control group regarding sciatic
and brain oxidant/antioxidant parameters. These ﬁndings
show no toxic eﬀect treatment with beta glucan in brain and
sciaticnervetissuesofdiabeticrats.Thus,itmaybepreferred
to use natural products in treating and preventing various
diseases.
Owing to their useful eﬀects on the immune system,
antioxidant, and anti-inﬂammatory properties, and because
they lack any toxic eﬀects, beta glucans have been used in
previous many studies [32, 33]. It has been suggested that
beta-glucansloweredpostprandialglycemia,hyperlipidemia,
and hypertension [34, 35]. Also, it is reported that beta
glucan improves wound healing in diabetic mice [36]. In
addition, it has been suggested that beta-glucans may be
usedtopreventortreatexcessivemicroglialactivationduring
chronic inﬂammatory conditions [37]. The present study is
the ﬁrst experimental research demonstrating the protective
eﬀectiveness of beta glucan to protect diabetes-induced
oxidative stress in brain and sciatic nerve of rats.
Gliclazide which is a another marker of drug of the
present study, second-generation sulfonylurea, might exert
antioxidant eﬀect. It has been demonstrated that gli-
clazide prevents, through its antioxidant properties, oxidized
low-density lipoprotein-associated endothelial dysfunction,
apoptosis, and plaque rupture [38]. It has been found that
gliclazide was able to signiﬁcantly reduce high glucose-
induced apoptosis, mitochondrial alterations, and nitrotyro-
sine concentration increase [39]. It has been suggested that it
decreases hyperglycemia and hyperinsulinemia and inhibits
oxidative stress. It is also a promising therapeutic candidate
for the prevention of vascular complications of diabetes, by
decreasing the level of DNA damage induced by reactive
oxygen species [13, 40]. Also it has been found that gliclazide
reduced oxidative stress in liver and kidney tissues of diabetic
rats[11,41].Buttheprotectiveeﬀectofgliclazideondiabetic
brain and sciatic nerve tissues has not been reported so
far, it is interested in whether antioxidative properties of
gliclazide may occur to reduction in oxidative damage, in
the context of prevention of diabetes-associated neuropathy
and encephalopathy. In the present study, treatment with
gliclazide of diabetic rats signiﬁcantly reduced TOS and OSI
levelscomparedtountreateddiabeticratsinbrainandsciatic
tissues but insigniﬁcant increased TAS level and catalase
activity. Because of the decrease in these oxidants and the
increase in these antioxidants, the oxidative/antioxidative
balance demonstrated to shift towards the antioxidative
status with gliclazide treatment in brain and sciatic nerve
tissues of diabetic rats. This study is the ﬁrst experimental
research demonstrating the eﬀectiveness of gliclazide to
protect diabetes-induced oxidative stress in brain and sciatic
nerve of rats. As a result, we may explain these results due to
the antioxidant and antidiabetic eﬀects of gliclazide.
Paraoxonase is one of the important antioxidant en-
zymes. PON-1 hydrolyses lipid peroxides in oxidized lipo-
proteins. A close relationship between PON-1 deﬁciency and
accelerated progression of arteriosclerosis has been found
in experimental and human studies [42, 43]. Although
microangiopathy plays a role in the pathogenesis of diabetic
neuropathy, there has been little research on PON-1 activity
in patients with DM. Therefore, PON-1 was selected as
a marker agent of antioxidant defences system in present
study. In a previous study, it has been found that serum
PON-1 decreased in diabetic rats and spermine reversed the
decline of PON-1 spermine-treated diabetic rats [44]. Also,
it has been indicated that cerebrospinal ﬂuid (CSF) levels
of β-glucan and gliclazide correlated in a dose-dependent
pattern with therapeutic response, and they penetrated to
blood-brain barrier [45, 46]. To our knowledge, brain and
sciatic nerve injury relationship between PON-1 activities
has not been studied in diabetic rats. In this study, we found
decreased PON-1 activity in the brain and sciatic tissues of
diabetic rats compared to control rats. Both beta glucan and
gliclazide treatments were reversed to decrement activity of
PON-1 in diabetic rats.
5. Conclusions
Hyperglicemia in STZ-induceddiabetic ratscancauseoxida-
tive damage in brain and sciatic nerve tissues, which may
play vital roles in the pathogenesis of diabetic neuropathy
and encephalopathy. Also treatment of beta glucan and/or
gliclazide inhibits lipid peroxidation and regulates total
oxidant/antioxidant status in diabetic rat brain and sciatic
nerve tissues. This study results suggested that beta glucan
and gliclazide may be considered to reduce oxidative stress
in diabetic brain and sciatic nerve and may be used as a
protective agent against diabetic damage of brain and sciatic
nerve.
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